{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:50:35Z","timestamp":1794027035306,"version":"4.8.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A decade ago, we described a new approach to discover next generation adjuvants, identifying small-molecule immune potentiators (SMIPs) as Toll-like receptor (TLR)7 agonists. We also optimally formulated these drugs through adsorption to aluminum salts (alum), allowing them to be evaluated with a range of established and early-stage vaccines. Early proof-of-concept studies showed that a TLR7 agonist (TLR7a)-based SMIP, when adsorbed to alum, could perform as an effective adjuvant for a variety of different antigens, in both small and large animals. Studies in rodents demonstrated that the adjuvant enhanced immunogenicity of a recombinant protein-based vaccine against <jats:italic>Staphylococcus aureus<\/jats:italic>, and also showed potential to improve existing vaccines against pertussis or meningococcal infection. Extensive evaluations showed that the adjuvant was effective in non-human primates (NHPs), exploiting a mechanism of action that was consistent across the different animal models. The adjuvant formulation (named AS37) has now been advanced into clinical evaluation. A systems biology-based evaluation of the phase I clinical data with a meningococcal C conjugate vaccine showed that the AS37-adjuvanted formulation had an acceptable safety profile, was potent, and activated the expected immune pathways in humans, which was consistent with observations from the NHP studies. In the intervening decade, several alternative TLR7 agonists have also emerged and advanced into clinical development, such as the alum adsorbed TLR7\/8 SMIP present in a widely distributed COVID-19 vaccine. This review summarizes the research and early development of the new adjuvant AS37, with an emphasis on the steps taken to allow its progression into clinical evaluations.<\/jats:p>","DOI":"10.1038\/s41541-024-00810-6","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T15:02:53Z","timestamp":1707404573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The scientific journey of a novel adjuvant (AS37) from bench to bedside"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7657-8605","authenticated-orcid":false,"given":"Ugo","family":"D\u2019Oro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek T.","family":"O\u2019Hagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"810_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","volume":"39","author":"G Del Giudice","year":"2018","unstructured":"Del Giudice, G., Rappuoli, R. & Didierlaurent, A. M. Correlates of adjuvanticity: a review on adjuvants in licensed vaccines. Semin. Immunol. 39, 14\u201321 (2018).","journal-title":"Semin. Immunol."},{"key":"810_CR2","doi-asserted-by":"publisher","first-page":"101426","DOI":"10.1016\/j.smim.2020.101426","volume":"50","author":"DT O\u2019Hagan","year":"2020","unstructured":"O\u2019Hagan, D. T., Lodaya, R. N. & Lofano, G. The continued advance of vaccine adjuvants\u2014\u2018we can work it out\u2019. Semin. Immunol. 50, 101426 (2020).","journal-title":"Semin. Immunol."},{"key":"810_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/d41586-023-01529-5","volume":"617","author":"VM Vidal","year":"2023","unstructured":"Vidal, V. M. \u2018A good day\u2019: FDA approves world\u2019s first RSV vaccine. Nature 617, 234\u2013235 (2023).","journal-title":"Nature"},{"key":"810_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3389\/fimmu.2017.00943","volume":"8","author":"W Burny","year":"2017","unstructured":"Burny, W. et al. Different adjuvants induce common innate pathways that are associated with enhanced adaptive responses against a model antigen in humans. Front Immunol. 8, 943 (2017).","journal-title":"Front Immunol."},{"key":"810_CR5","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.vaccine.2019.02.015","volume":"37","author":"W Burny","year":"2019","unstructured":"Burny, W. et al. Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans. Vaccine 37, 2004\u20132015 (2019).","journal-title":"Vaccine"},{"key":"810_CR6","doi-asserted-by":"publisher","first-page":"eaay8618","DOI":"10.1126\/scitranslmed.aay8618","volume":"12","author":"L De Mot","year":"2020","unstructured":"De Mot, L. et al. Transcriptional profiles of adjuvanted hepatitis B vaccines display variable interindividual homogeneity but a shared core signature. Sci. Transl. Med. 12, eaay8618 (2020).","journal-title":"Sci. Transl. Med."},{"key":"810_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.clim.2016.05.007","volume":"169","author":"G Leroux-Roels","year":"2016","unstructured":"Leroux-Roels, G. et al. Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: results from a phase II, randomized, multicenter trial. Clin. Immunol. 169, 16\u201327 (2016).","journal-title":"Clin. Immunol."},{"key":"810_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00337-0","volume":"6","author":"S Budroni","year":"2021","unstructured":"Budroni, S. et al. Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants. Npj. Vaccines 6, 78 (2021).","journal-title":"Npj. Vaccines"},{"key":"810_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00613-1","volume":"8","author":"C Loos","year":"2023","unstructured":"Loos, C. et al. Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design. NPJ. Vaccines 8, 34 (2023).","journal-title":"NPJ. Vaccines"},{"key":"810_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20346-w","volume":"12","author":"DJ Dowling","year":"2022","unstructured":"Dowling, D. J. et al. Development of a TLR7\/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination. Sci. Rep. 12, 16860 (2022).","journal-title":"Sci. Rep."},{"key":"810_CR11","doi-asserted-by":"publisher","first-page":"13466","DOI":"10.1021\/acs.jmedchem.0c01049","volume":"63","author":"S Federico","year":"2020","unstructured":"Federico, S. et al. Modulation of the innate immune response by targeting toll-like receptors: a perspective on their agonists and antagonists. J. Med. Chem. 63, 13466\u201313513 (2020).","journal-title":"J. Med. Chem."},{"key":"810_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/vaccines2020323","volume":"2","author":"DN Toussi","year":"2014","unstructured":"Toussi, D. N. & Massari, P. Immune adjuvant effect of molecularly-defined toll-like receptor ligands. Vaccines (Basel) 2, 323\u2013353 (2014).","journal-title":"Vaccines (Basel)"},{"key":"810_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","volume":"20","author":"B Pulendran","year":"2021","unstructured":"Pulendran, B., Arunachalam, S. & O\u2019Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454\u2013475 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"810_CR14","doi-asserted-by":"publisher","first-page":"940715","DOI":"10.3389\/fimmu.2022.940715","volume":"13","author":"F Dotiwala","year":"2022","unstructured":"Dotiwala, F. & Upadhyay, A. K. A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects. Front Immunol. 13, 940715 (2022).","journal-title":"Front Immunol."},{"key":"810_CR15","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1016\/j.celrep.2018.11.081","volume":"25","author":"Z Zhang","year":"2018","unstructured":"Zhang, Z. et al. Structural analyses of toll-like receptor 7 reveal detailed RNA sequence specificity and recognition mechanism of agonistic ligands. Cell Rep. 25, 3371\u20133381 (2018).","journal-title":"Cell Rep."},{"key":"810_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.4049\/jimmunol.1500530","volume":"195","author":"T Eigenbrod","year":"2015","unstructured":"Eigenbrod, T. & Dalpke, A. H. Bacterial RNA: an underestimated stimulus for innate immune responses. J. Immunol. 195, 411\u2013418 (2015).","journal-title":"J. Immunol."},{"key":"810_CR17","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.molimm.2009.11.003","volume":"47","author":"J Liu","year":"2010","unstructured":"Liu, J. et al. A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition. Mol. Immunol. 47, 1083\u20131090 (2010).","journal-title":"Mol. Immunol."},{"key":"810_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.gene.2012.04.007","volume":"503","author":"T Mikami","year":"2012","unstructured":"Mikami, T., Miyashita, H., Takatsuka, S., Kuroki, Y. & Matsushima, N. Molecular evolution of vertebrate Toll-like receptors: evolutionary rate difference between their leucine-rich repeats and their TIR domains. Gene 503, 235\u2013243 (2012).","journal-title":"Gene"},{"key":"810_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.0105-2896.2004.00144.x","volume":"199","author":"B Pulendran","year":"2004","unstructured":"Pulendran, B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev. 199, 227\u2013250 (2004).","journal-title":"Immunol. Rev."},{"key":"810_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/MOP.0000000000000868","volume":"32","author":"E Nanishi","year":"2020","unstructured":"Nanishi, E., Dowling, D. J. & Levy, O. Toward precision adjuvants: optimizing science and safety. Curr. Opin. Pediatr. 32, 125\u2013138 (2020).","journal-title":"Curr. Opin. Pediatr."},{"key":"810_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3389\/fimmu.2014.00255","volume":"5","author":"L Cohn","year":"2014","unstructured":"Cohn, L. & Delamarre, L. Dendritic cell-targeted vaccines. Front. Immunol. 5, 255 (2014).","journal-title":"Front. Immunol."},{"key":"810_CR22","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1586\/14760584.2013.811208","volume":"12","author":"JP Vasilakos","year":"2013","unstructured":"Vasilakos, J. P. & Tomai, M. A. The use of Toll-like receptor 7\/8 agonists as vaccine adjuvants. Expert. Rev. Vaccines 12, 809\u2013819 (2013).","journal-title":"Expert. Rev. Vaccines"},{"key":"810_CR23","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.3390\/pharmaceutics14102076","volume":"14","author":"S Tambunlertchai","year":"2022","unstructured":"Tambunlertchai, S., Geary, S. M. & Salem, A. K. Topically applied resiquimod versus imiquimod as a potential adjuvant in melanoma treatment. Pharmaceutics 14, 2076 (2022).","journal-title":"Pharmaceutics"},{"key":"810_CR24","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1086\/429238","volume":"40","author":"C Miranda-Ver\u00e1stegui","year":"2005","unstructured":"Miranda-Ver\u00e1stegui, C., Llanos-Cuentas, A., Arevalo, I., Ward, B. J. & Matlashewski, G. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin. Infect. Dis. 40, 1395\u20131403 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"810_CR25","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/j.vaccine.2009.02.029","volume":"27","author":"D Fraillery","year":"2009","unstructured":"Fraillery, D., Zosso, N. & Nardelli-Haefliger, D. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles. Vaccine 27, 2326\u20132334 (2009).","journal-title":"Vaccine"},{"key":"810_CR26","doi-asserted-by":"publisher","first-page":"7676","DOI":"10.4049\/jimmunol.174.12.7676","volume":"174","author":"U Wille-Reece","year":"2005","unstructured":"Wille-Reece, U., Wu, C. Y., Flynn, B. J., Kedl, R. M. & Seder, R. A. Immunization with HIV-1 Gag protein conjugated to a TLR7\/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J. Immunol. 174, 7676\u20137683 (2005).","journal-title":"J. Immunol."},{"key":"810_CR27","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1128\/IAI.00974-08","volume":"77","author":"C Othoro","year":"2009","unstructured":"Othoro, C. et al. Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic toll-like receptor 7 agonist, imiquimod. Infect. Immun. 77, 739\u2013748 (2009).","journal-title":"Infect. Immun."},{"key":"810_CR28","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/cid\/ciu582","volume":"59","author":"IF Hung","year":"2014","unstructured":"Hung, I. F. et al. Immunogenicity of intradermal trivalent influenza vaccine with topical imiquimod: a double blind randomized controlled trial. Clin. Infect. Dis. 59, 1246\u20131255 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"810_CR29","doi-asserted-by":"publisher","first-page":"113803","DOI":"10.1016\/j.addr.2021.05.013","volume":"175","author":"S Bhagchandani","year":"2021","unstructured":"Bhagchandani, S., Johnson, J. A. & Irvine, D. J. Evolution of toll-like receptor 7\/8 agonist therapeutics and their delivery approaches: from antiviral formulations to vaccine adjuvants. Adv. Drug Deliv. Rev. 175, 113803 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"810_CR30","doi-asserted-by":"publisher","first-page":"263ra160","DOI":"10.1126\/scitranslmed.3009980","volume":"6","author":"TY Wu","year":"2014","unstructured":"Wu, T. Y. et al. Rational design of small molecules as vaccine adjuvants. Sci. Transl. Med. 6, 263ra160 (2014).","journal-title":"Sci. Transl. Med."},{"key":"810_CR31","doi-asserted-by":"publisher","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","volume":"183","author":"AM Didierlaurent","year":"2009","unstructured":"Didierlaurent, A. M. et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183, 6186\u20136197 (2009).","journal-title":"J. Immunol."},{"key":"810_CR32","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","volume":"193","author":"AM Didierlaurent","year":"2014","unstructured":"Didierlaurent, A. M. et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J. Immunol. 193, 1920\u20131930 (2014).","journal-title":"J. Immunol."},{"key":"810_CR33","doi-asserted-by":"publisher","first-page":"eaal2094","DOI":"10.1126\/scitranslmed.aal2094","volume":"9","author":"F Liang","year":"2017","unstructured":"Liang, F. et al. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. Sci. Transl. Med. 9, eaal2094 (2017).","journal-title":"Sci. Transl. Med."},{"key":"810_CR34","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.vaccine.2022.12.006","volume":"41","author":"E Siena","year":"2023","unstructured":"Siena, E. et al. Systems analysis of human responses to an aluminium hydroxide-adsorbed TLR7 agonist (AS37) adjuvanted vaccine reveals a dose-dependent and specific activation of the interferon-mediated antiviral response. Vaccine 41, 724\u2013734 (2023).","journal-title":"Vaccine"},{"key":"810_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0089-x","volume":"3","author":"H Hogenesch","year":"2018","unstructured":"Hogenesch, H., O\u2019Hagan, D. T. & Fox, C. B. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ. Vaccines 3, 51 (2018).","journal-title":"NPJ. Vaccines"},{"key":"810_CR36","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1002\/eji.201242372","volume":"42","author":"A Mori","year":"2012","unstructured":"Mori, A. et al. The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses. Eur. J. Immunol. 42, 2709\u20132719 (2012).","journal-title":"Eur. J. Immunol."},{"key":"810_CR37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2165\/11591760-000000000-00000","volume":"25","author":"N Gar\u00e7on","year":"2011","unstructured":"Gar\u00e7on, N. et al. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs. 25, 217\u2013226 (2011).","journal-title":"BioDrugs."},{"key":"810_CR38","first-page":"380","volume":"22","author":"Q Yin","year":"2023","unstructured":"Yin, Q. et al. A TLR7-nanoparticle adjuvant promotes a broad immune response against heterologous strains of influenza and SARS-CoV-2. Nat. Mater. 22, 380\u2013390 (2023).","journal-title":"Nat. Mater."},{"key":"810_CR39","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","volume":"50","author":"S Crotty","year":"2019","unstructured":"Crotty, S. T Follicular helper cell biology: a decade of discovery and diseases. Immunity 50, 1132\u20131148 (2019).","journal-title":"Immunity"},{"key":"810_CR40","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.xphs.2018.01.024","volume":"107","author":"P Malyala","year":"2018","unstructured":"Malyala, P. et al. The preparation and physicochemical characterization of aluminum hydroxide\/TLR7a, a novel vaccine adjuvant comprising a small molecule adsorbed to aluminum hydroxide. J. Pharm. Sci. 107, 1577\u20131585 (2018).","journal-title":"J. Pharm. Sci."},{"key":"810_CR41","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1021\/acs.jmedchem.6b00489","volume":"59","author":"A Cortez","year":"2016","unstructured":"Cortez, A. et al. Incorporation of phosphonate into benzonaphthyridine Toll-like receptor 7 agonists for adsorption to aluminum hydroxide. J. Med Chem. 59, 5868\u20135878 (2016).","journal-title":"J. Med Chem."},{"key":"810_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/srep29063","volume":"6","author":"C Buonsanti","year":"2016","unstructured":"Buonsanti, C. et al. Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines. Sci. Rep. 6, 29063 (2016).","journal-title":"Sci. Rep."},{"key":"810_CR43","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1073\/pnas.1424924112","volume":"112","author":"F Bagnoli","year":"2015","unstructured":"Bagnoli, F. et al. Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus. Proc. Natl Acad. Sci. USA 112, 3680\u20133685 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"810_CR44","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1182\/bloodadvances.2017011411","volume":"1","author":"JR Francica","year":"2017","unstructured":"Francica, J. R. et al. Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. Blood Adv. 1, 2329\u20132342 (2017).","journal-title":"Blood Adv."},{"key":"810_CR45","doi-asserted-by":"publisher","first-page":"705360","DOI":"10.3389\/fimmu.2021.705360","volume":"12","author":"J Clegg","year":"2021","unstructured":"Clegg, J. et al. Staphylococcus aureus vaccine research and development: the past, present and future, including novel therapeutic strategies. Front Immunol. 12, 705360 (2021).","journal-title":"Front Immunol."},{"key":"810_CR46","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1016\/j.vaccine.2017.08.009","volume":"35","author":"A Misiak","year":"2017","unstructured":"Misiak, A. et al. Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model. Vaccine 35, 5256\u20135263 (2017).","journal-title":"Vaccine"},{"key":"810_CR47","doi-asserted-by":"publisher","first-page":"e0147767","DOI":"10.1371\/journal.pone.0147767","volume":"11","author":"F Mancini","year":"2016","unstructured":"Mancini, F. et al. One dose of staphylococcus aureus 4C-staph vaccine formulated with a Novel TLR7-dependent adjuvant rapidly protects mice through antibodies, effector CD4+ T cells, and IL-17A. PLoS. One 11, e0147767 (2016).","journal-title":"PLoS. One"},{"key":"810_CR48","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/vaccines8040621","volume":"8","author":"CN Chasaide","year":"2020","unstructured":"Chasaide, C. N. & Mills, K. H. G. Next-generation Pertussis vaccines based on the induction of protective T cells in the respiratory tract. Vaccines (Basel) 8, 621 (2020).","journal-title":"Vaccines (Basel)"},{"key":"810_CR49","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3389\/fimmu.2018.00641","volume":"9","author":"HTM Vo","year":"2018","unstructured":"Vo, H. T. M. et al. Alum\/Toll-Like receptor 7 adjuvant enhances the expansion of memory B cell compartment within the draining lymph node. Front Immunol. 9, 641 (2018).","journal-title":"Front Immunol."},{"key":"810_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7565","volume":"6","author":"JR Francica","year":"2015","unstructured":"Francica, J. R. et al. Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization. Nat. Commun. 6, 6565 (2015).","journal-title":"Nat. Commun."},{"key":"810_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00472-2","volume":"7","author":"L Grigoryan","year":"2022","unstructured":"Grigoryan, L. et al. Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice. NPJ Vaccines 7, 55 (2022).","journal-title":"NPJ Vaccines"},{"key":"810_CR52","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41586-021-03530-2","volume":"594","author":"PS Arunachalam","year":"2021","unstructured":"Arunachalam, P. S. et al. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature 594, 253\u2013258 (2021).","journal-title":"Nature"},{"key":"810_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2017.06.006","volume":"47","author":"EA Thompson","year":"2017","unstructured":"Thompson, E. A. & Lor\u00e9, K. Non-human primates as a model for understanding the mechanism of action of toll-like receptor-based vaccine adjuvants. Curr. Opin. Immunol. 47, 1\u20137 (2017).","journal-title":"Curr. Opin. Immunol."},{"key":"810_CR54","doi-asserted-by":"publisher","first-page":"108275","DOI":"10.1016\/j.clim.2019.108275","volume":"209","author":"A Gonzalez-Lopez","year":"2019","unstructured":"Gonzalez-Lopez, A. et al. Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): a phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine. Clin. Immunol. 209, 108275 (2019).","journal-title":"Clin. Immunol."},{"key":"810_CR55","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1517\/14712598.2.1.87","volume":"2","author":"R Lakshman","year":"2002","unstructured":"Lakshman, R. & Finn, A. Meningococcal serogroup C conjugate vaccine. Expert. Opin. Biol. Ther. 2, 87\u201396 (2002).","journal-title":"Expert. Opin. Biol. Ther."},{"key":"810_CR56","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/cid\/cir198","volume":"52","author":"JB Wing","year":"2011","unstructured":"Wing, J. B. et al. Kinetics of immune responses to nasal challenge with meningococcal polysaccharide one year after serogroup-C glycoconjugate vaccination. Clin. Infect. Dis. 52, 1317\u20131323 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"810_CR57","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jinf.2020.05.079","volume":"81","author":"SR Parikh","year":"2020","unstructured":"Parikh, S. R. et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J. Infect. 81, 483\u2013498 (2020).","journal-title":"J. Infect."},{"key":"810_CR58","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1365-2796.2008.02050.x","volume":"265","author":"C Guiducci","year":"2009","unstructured":"Guiducci, C., Coffman, R. L. & Barrat, F. J. Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. J. Intern. Med. 265, 43\u201357 (2009).","journal-title":"J. Intern. Med."},{"key":"810_CR59","doi-asserted-by":"publisher","first-page":"e01844","DOI":"10.1128\/JVI.01844-16","volume":"91","author":"SP Kasturi","year":"2017","unstructured":"Kasturi, S. P. et al. Adjuvanting a simian immunodeficiency virus vaccine with toll-like receptor ligands encapsulated in nanoparticles induces persistent antibody responses and enhanced protection in TRIM5alpha restrictive macaques. J. Virol. 91, e01844\u201316 (2017).","journal-title":"J. Virol."},{"key":"810_CR60","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jconrel.2016.11.011","volume":"244","author":"CB Fox","year":"2016","unstructured":"Fox, C. B. et al. Adsorption of a synthetic TLR7\/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach. J. Control Release 244, 98\u2013107 (2016).","journal-title":"J. Control Release"},{"key":"810_CR61","doi-asserted-by":"publisher","first-page":"1053550","DOI":"10.3389\/fimmu.2023.1053550","volume":"14","author":"M Panigaj","year":"2023","unstructured":"Panigaj, M. et al. Therapeutic immunomodulation by rationally designed nucleic acids and nucleic acid nanoparticles. Front Immunol. 14, 1053550 (2023).","journal-title":"Front Immunol."},{"key":"810_CR62","doi-asserted-by":"publisher","first-page":"e0169521","DOI":"10.1128\/spectrum.01695-21","volume":"10","author":"C Counoupas","year":"2022","unstructured":"Counoupas, C. et al. High-Titer neutralizing antibodies against the SARS-CoV-2 delta variant induced by Alhydroxyquim-II-Adjuvanted trimeric spike antigens. Microbiol. Spectr. 10, e0169521 (2022).","journal-title":"Microbiol. Spectr."},{"key":"810_CR63","doi-asserted-by":"publisher","first-page":"9467","DOI":"10.1002\/anie.202015362","volume":"60","author":"S Jangra","year":"2021","unstructured":"Jangra, S. et al. Sterilizing immunity against SARS-CoV-2 infection in mice by a single-shot and lipid amphiphile imidazoquinoline TLR7\/8 agonist-adjuvanted recombinant spike protein vaccine*. Angew. Chem. Int. Ed. Engl. 60, 9467\u20139473 (2021).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"810_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23942-y","volume":"12","author":"NK Routhu","year":"2021","unstructured":"Routhu, N. K. et al. SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung. Nat. Commun. 12, 3587 (2021).","journal-title":"Nat. Commun."},{"key":"810_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21639-w","volume":"12","author":"PD Yadav","year":"2021","unstructured":"Yadav, P. D. et al. Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. Nat. Commun. 12, 1386 (2021).","journal-title":"Nat. Commun."},{"key":"810_CR66","doi-asserted-by":"publisher","first-page":"102298","DOI":"10.1016\/j.isci.2021.102298","volume":"24","author":"B Ganneru","year":"2021","unstructured":"Ganneru, B. et al. Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation. iScience 24, 102298 (2021).","journal-title":"iScience"},{"key":"810_CR67","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","volume":"21","author":"R Ella","year":"2021","unstructured":"Ella, R. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect. Dis. 21, 637\u2013646 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"810_CR68","doi-asserted-by":"publisher","first-page":"102424","DOI":"10.1016\/j.dsx.2022.102424","volume":"16","author":"AK Singh","year":"2022","unstructured":"Singh, A. K. et al. Humoral antibody kinetics with ChAdOx1-nCOV (Covishield) and BBV-152 (Covaxin) vaccine among Indian healthcare workers: a 6-month longitudinal cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. Diabetes Metab. Syndr. 16, 102424 (2022).","journal-title":"Diabetes Metab. Syndr."},{"key":"810_CR69","unstructured":"WHO. WHO Issues Emergency Use Listing for Eighth COVID-19 Vaccine. https:\/\/www.who.int\/news\/item\/03-11-2021-who-issues-emergency-use-listing-for-eighth-covid-19-vaccine (2023)."},{"key":"810_CR70","doi-asserted-by":"publisher","first-page":"e1000138","DOI":"10.1371\/journal.ppat.1000138","volume":"4","author":"F Geeraedts","year":"2008","unstructured":"Geeraedts, F. et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog. 4, e1000138 (2008).","journal-title":"PLoS Pathog."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00810-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00810-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00810-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T18:02:46Z","timestamp":1707674566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00810-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["810"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-00810-6","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]},"assertion":[{"value":"2 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Both authors are employees of the GSK group of companies and hold shares in the GSK group of companies. Both are listed as inventors on patents owned by the GSK group of companies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}